Disseminated Intravascular Coagulation Following Idarucizumab and Andexanet Alfa: Assessment of a Signal of Disproportionate Reporting From the Food and Drugs Administration Adverse Event Reporting System (FAERS) Database
-
By
-
March 22, 2026
Objective:
To analyze the FDA Adverse Event Reporting System (FAERS) database for potential safety signals related to disseminated intravascular coagulation (DIC) incidents following the administration of idarucizumab and andexanet alfa, emphasizing the importance of identifying safety signals.
Key Findings:
- Identified 11 cases of DIC following idarucizumab and 5 cases following andexanet alfa, with some cases having a short time to onset (≥ 1 day), suggesting a possible association with the antidotes, warranting further investigation.
- No strong evidence to support a definitive safety signal, but the life-threatening nature of DIC warrants further investigation.
Interpretation:
While alternative causes for DIC exist, the timing and biological plausibility suggest a potential link to the use of idarucizumab and andexanet alfa, necessitating further research and consideration in clinical practice.
Limitations:
- Rarity of DIC and limited use of the medications may restrict data availability.
- Spontaneous reporting may not capture all relevant cases or events, introducing potential biases.
Conclusion:
Further investigations are essential due to the serious implications of DIC, and healthcare professionals should report any adverse events related to these medications to enhance pharmacovigilance.
